Table 2.

Gene expression following chronic FGF21 treatment.

	Wild type				FR1KO
	Vehicle	0.1 mg/kg	0.3 mg/kg	1 mg/kg	Vehicle	0.1 mg/kg	0.3 mg/kg	1 mg/kg
White adipose tissue
ACADL	0.53 (0.06)	0.72 (0.11)	0.59 (0.06)	0.74 (0.11)⁎	0.75 (0.05)	0.57 (0.06)	0.80 (0.04)	0.69 (0.04)
ACADVL	0.25 (0.04)	0.41 (0.06)⁎⁎	0.32 (0.02)	0.55 (0.12)⁎	0.34 (0.04)	0.28 (0.04)	0.48 (0.04)	0.30 (0.04)
PGC1α	0.08 (0.01)	0.11 (0.02)	0.12 (0.01)	0.14 (0.02)⁎	0.07 (0.01)	0.07 (0.01)	0.10 (0.01)	0.08 (0.01)
UCP1	0.23 (0.03)	0.42 (0.15)	1.16 (0.32)⁎	1.87 (0.49)⁎	0.31 (0.09)	0.41 (0.09)	0.68 (0.46)	0.83 (0.45)
Brown adipose tissue
CPT1a	0.16 (0.02)	0.20 (0.03)	0.22 (0.03)⁎	0.022 (0.03)⁎	0.17 (0.01)	0.13 (0.03)	0.16 (0.02)	0.19 (0.05)
DIO2	0.08 (0.02)	0.20 (0.06)⁎	0.13 (0.03)	0.13 (0.02)⁎	0.09 (0.01)	0.04 (0.01)	0.10 (0.01)	0.09 (0.02)
UCP1	47.81 (4.51)	92.18 (41.57)	66.62 (9.18)	110.14 (21.53)⁎	53.29 (20.85)	34.36 (6.07)	44.02 (11.74)	58.17 (17.12)
Liver
CYP7a1	1.08 (0.20)	1.16 (0.32)	1.42 (0.33)	1.74 (0.32)	0.89 (0.12)	0.83 (0.27)	1.03 (0.15)	1.03 (0.14)
CYP8b1	3.83 (0.28)	4.89 (0.54)	4.61 (0.65)	4.42 (0.60)	3.51 (0.27)	2.99 (0.44)	3.59 (0.40)	3.59 (0.46)
LEPR	0.03 (0.01)	0.03 (0.01)	0.11 (0.02)⁎	0.15 (0.03)⁎	0.03 (0.01)	0.04 (0.01)	0.03 (0.01)	0.03 (0.01)
SCD1	29.94 (3.3)	18.73 (4.67)	15.90 (2.66)⁎	9.70 (3.51)⁎	35.69 (4.89)	38.11 (7.48)	26.82 (4.26)	26.82 (3.21)⁎

To determine if the transcriptional events downstream of FGFR1 activation were altered we examined gene expression in metabolically relevant tissues. Data are presented as mean ±SEM in brackets. Statistical analysis was performed using one-way ANOVA, followed by Dunnett's multiple comparisons test where appropriate. Differences were considered significant when P≤0.05 and are denoted by *.